These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 29462402)
1. Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Katsanos KH; Papamichael K; Cheifetz AS; Christodoulou DK Inflamm Bowel Dis; 2018 Feb; 24(3):465-466. PubMed ID: 29462402 [No Abstract] [Full Text] [Related]
2. Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Fiorino G; Ruiz-Argüello MB; Maguregui A; Nagore D; Correale C; Radice S; Gilardi D; Allocca M; Furfaro F; Martínez A; Danese S Inflamm Bowel Dis; 2018 Feb; 24(3):601-606. PubMed ID: 29462398 [TBL] [Abstract][Full Text] [Related]
3. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review. Martelli L; Peyrin-Biroulet L Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715 [TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease. Lovero R; Losurdo G; La Fortezza RF; Terracciano F; Biscaglia G; Martino G; Nardella M; Di Leo A; Principi M; Andriulli A; Bossa F Eur J Gastroenterol Hepatol; 2021 Feb; 32(2):201-207. PubMed ID: 33369956 [TBL] [Abstract][Full Text] [Related]
5. Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study. Trystram N; Abitbol V; Tannoury J; Lecomte M; Assaraf J; Malamut G; Gagnière C; Barré A; Sobhani I; Chaussade S; Amiot A Aliment Pharmacol Ther; 2021 Apr; 53(8):887-899. PubMed ID: 33647174 [TBL] [Abstract][Full Text] [Related]
6. The Experience with Biosimilars of Infliximab in Rheumatic Diseases. Azevedo VF; Kos IA; Ariello L Curr Pharm Des; 2017; 23(44):6752-6758. PubMed ID: 29189135 [TBL] [Abstract][Full Text] [Related]
7. An in vitro comparison of four different immunoassays for the monitoring of Infliximab biosimilars drug levels. Neveu B; Kunst A; Prosser C; Robitaille R Clin Biochem; 2020 Apr; 78():58-62. PubMed ID: 31982376 [TBL] [Abstract][Full Text] [Related]
8. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review. Radin M; Sciascia S; Roccatello D; Cuadrado MJ BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633 [TBL] [Abstract][Full Text] [Related]
9. Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice. Lauret A; Moltó A; Abitbol V; Gutermann L; Conort O; Chast F; Goulvestre C; Le Jeunne C; Chaussade S; Roux C; Batteux F; Dougados M; Allanore Y; Avouac J Semin Arthritis Rheum; 2020 Dec; 50(6):1449-1456. PubMed ID: 32268935 [TBL] [Abstract][Full Text] [Related]
10. Biosimilars in the therapy of inflammatory bowel diseases. Hlavaty T; Letkovsky J Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561 [TBL] [Abstract][Full Text] [Related]
12. Progress with infliximab biosimilars for inflammatory bowel disease. Kurti Z; Gonczi L; Lakatos PL Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797 [TBL] [Abstract][Full Text] [Related]
13. Does Similarity Breed Contempt? A Review of the Use of Biosimilars in Inflammatory Bowel Disease. Bhat S; Limdi JK; Cross RK; Farraye FA Dig Dis Sci; 2021 Aug; 66(8):2513-2532. PubMed ID: 34176024 [TBL] [Abstract][Full Text] [Related]
14. Update on biosimilars in inflammatory bowel disease: Position and recommendations in Mexico. Mayoral-Zavala A; Esquivel-Aguilar A; Del Real-Calzada CM; Gutiérrez-Grobe Y; Ramos-García J; Rocha-Ramírez JL; Rojas-Illanes MF; Rubio-Martínez B; Sánchez-Chávez X; Yamamoto-Furusho JK; Rev Gastroenterol Mex (Engl Ed); 2018; 83(4):414-423. PubMed ID: 29685744 [TBL] [Abstract][Full Text] [Related]
15. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications? Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532 [TBL] [Abstract][Full Text] [Related]
16. Biosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects. Gecse KB; Lakatos PL Drugs; 2016 Oct; 76(15):1413-1420. PubMed ID: 27638739 [TBL] [Abstract][Full Text] [Related]
17. Biosimilars in ulcerative colitis: When and for who? Ilias A; Gonczi L; Kurti Z; Lakatos PL Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937 [TBL] [Abstract][Full Text] [Related]